160 related articles for article (PubMed ID: 19240653)
1. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Purnell PR; Mack PC; Tepper CG; Evans CP; Green TP; Gumerlock PH; Lara PN; Gandara DR; Kung HJ; Gautschi O
J Thorac Oncol; 2009 Apr; 4(4):448-54. PubMed ID: 19240653
[TBL] [Abstract][Full Text] [Related]
2. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
[TBL] [Abstract][Full Text] [Related]
3. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
4. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Schweppe RE; Kerege AA; French JD; Sharma V; Grzywa RL; Haugen BR
J Clin Endocrinol Metab; 2009 Jun; 94(6):2199-203. PubMed ID: 19293266
[TBL] [Abstract][Full Text] [Related]
6. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Hiscox S; Jordan NJ; Smith C; James M; Morgan L; Taylor KM; Green TP; Nicholson RI
Breast Cancer Res Treat; 2009 May; 115(1):57-67. PubMed ID: 18493848
[TBL] [Abstract][Full Text] [Related]
9. The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
Yun HS; Lee J; Kil WJ; Kramp TR; Tofilon PJ; Camphausen K
Mol Cancer Ther; 2021 Sep; 20(9):1672-1679. PubMed ID: 34158343
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
[TBL] [Abstract][Full Text] [Related]
11. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
12. Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Andersen P; Villingshøj M; Poulsen HS; Stockhausen MT
Cancer Invest; 2009 Feb; 27(2):178-83. PubMed ID: 19235590
[TBL] [Abstract][Full Text] [Related]
13. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Rothschild SI; Gautschi O; Batliner J; Gugger M; Fey MF; Tschan MP
Lung Cancer; 2017 May; 107():73-83. PubMed ID: 27372519
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
[TBL] [Abstract][Full Text] [Related]
17. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
[TBL] [Abstract][Full Text] [Related]
18. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.
Pham NA; Magalhaes JM; Do T; Schwock J; Dhani N; Cao PJ; Hill RP; Hedley DW
Int J Cancer; 2009 Jan; 124(2):280-6. PubMed ID: 18924149
[TBL] [Abstract][Full Text] [Related]
19. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
20. Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.
Ferguson J; Arozarena I; Ehrhardt M; Wellbrock C
Oncogene; 2013 Jan; 32(1):86-96. PubMed ID: 22310287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
